Biotricity Recognized by Financial Times as One of 2025’s Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed
Biotricity (OTCQB: BTCY) has been named one of the Americas' Fastest-Growing Companies 2025 by the Financial Times, achieving remarkable growth of 256.4% between 2020 and 2023. The company, specializing in Technology-as-a-Service for diagnostic and chronic disease management solutions, has demonstrated exceptional performance despite global challenges including the COVID-19 pandemic and supply chain disruptions.
The recognition comes as Biotricity addresses a critical healthcare gap, with over 100 million Americans facing barriers to accessing essential healthcare services. The company's proprietary remote monitoring technologies have particularly impacted high-risk cardiac patients, enabling medical providers to deliver faster interventions both in the U.S. and internationally.
The complete Financial Times report will be published on April 25, 2025, available to U.S. newspaper subscribers and globally on ft.com.
Biotricity (OTCQB: BTCY) è stata nominata una delle aziende a più rapida crescita delle Americhe per il 2025 dal Financial Times, registrando una crescita straordinaria del 256,4% tra il 2020 e il 2023. L'azienda, specializzata in Technology-as-a-Service per soluzioni di gestione diagnostica e delle malattie croniche, ha dimostrato prestazioni eccezionali nonostante le sfide globali, tra cui la pandemia di COVID-19 e le interruzioni della catena di approvvigionamento.
Il riconoscimento arriva mentre Biotricity affronta un'importante lacuna nel settore sanitario, con oltre 100 milioni di americani che affrontano barriere nell'accesso ai servizi sanitari essenziali. Le tecnologie di monitoraggio remoto proprietarie dell'azienda hanno avuto un impatto particolare sui pazienti cardiaci ad alto rischio, consentendo ai fornitori di assistenza medica di fornire interventi più rapidi sia negli Stati Uniti che a livello internazionale.
Il rapporto completo del Financial Times sarà pubblicato il 25 aprile 2025, disponibile per gli abbonati ai giornali statunitensi e a livello globale su ft.com.
Biotricity (OTCQB: BTCY) ha sido nombrada una de las empresas de más rápido crecimiento en las Américas para 2025 por el Financial Times, logrando un crecimiento notable del 256.4% entre 2020 y 2023. La compañía, especializada en Technology-as-a-Service para soluciones de gestión de diagnóstico y enfermedades crónicas, ha demostrado un rendimiento excepcional a pesar de los desafíos globales, incluida la pandemia de COVID-19 y las interrupciones en la cadena de suministro.
El reconocimiento llega mientras Biotricity aborda una brecha crítica en la atención médica, con más de 100 millones de estadounidenses enfrentando barreras para acceder a servicios de salud esenciales. Las tecnologías de monitoreo remoto patentadas de la compañía han impactado particularmente a los pacientes cardíacos de alto riesgo, permitiendo a los proveedores médicos ofrecer intervenciones más rápidas tanto en EE. UU. como a nivel internacional.
El informe completo del Financial Times se publicará el 25 de abril de 2025, disponible para suscriptores de periódicos en EE. UU. y globalmente en ft.com.
Biotricity (OTCQB: BTCY)는 Financial Times에 의해 2025년 아메리카에서 가장 빠르게 성장하는 기업 중 하나로 선정되었으며, 2020년부터 2023년까지 256.4%의 놀라운 성장을 기록했습니다. 이 회사는 진단 및 만성 질환 관리 솔루션을 위한 Technology-as-a-Service를 전문으로 하며, COVID-19 팬데믹과 공급망 중단 등 글로벌 도전 과제에도 불구하고 뛰어난 성과를 보여주었습니다.
이 인식은 Biotricity가 필수 의료 서비스에 접근하는 데 장벽을 겪고 있는 1억 명 이상의 미국인을 대상으로 중요한 의료 격차를 해결하고 있는 가운데 이루어졌습니다. 회사의 독점 원격 모니터링 기술은 특히 고위험 심장 환자에게 큰 영향을 미쳤으며, 의료 제공자가 미국과 국제적으로 더 빠른 개입을 제공할 수 있도록 했습니다.
Financial Times의 전체 보고서는 2025년 4월 25일에 발표되며, 미국 신문 구독자와 전 세계적으로 ft.com에서 이용할 수 있습니다.
Biotricity (OTCQB: BTCY) a été désignée comme l'une des entreprises à la croissance la plus rapide des Amériques pour 2025 par le Financial Times, avec une croissance remarquable de 256,4% entre 2020 et 2023. L'entreprise, spécialisée dans la Technology-as-a-Service pour des solutions de gestion des diagnostics et des maladies chroniques, a démontré des performances exceptionnelles malgré les défis mondiaux, y compris la pandémie de COVID-19 et les perturbations de la chaîne d'approvisionnement.
Cette reconnaissance intervient alors que Biotricity s'attaque à une lacune critique dans les soins de santé, avec plus de 100 millions d'Américains faisant face à des obstacles pour accéder à des services de santé essentiels. Les technologies de surveillance à distance propriétaires de l'entreprise ont particulièrement eu un impact sur les patients cardiaques à haut risque, permettant aux prestataires de soins de santé de fournir des interventions plus rapides tant aux États-Unis qu'à l'international.
Le rapport complet du Financial Times sera publié le 25 avril 2025, disponible pour les abonnés aux journaux américains et à l'échelle mondiale sur ft.com.
Biotricity (OTCQB: BTCY) wurde vom Financial Times als eines der am schnellsten wachsenden Unternehmen in den Amerikas für 2025 ausgezeichnet und erzielte ein bemerkenswertes Wachstum von 256,4% zwischen 2020 und 2023. Das Unternehmen, das sich auf Technology-as-a-Service für diagnostische und chronische Krankheitsmanagementlösungen spezialisiert hat, hat trotz globaler Herausforderungen wie der COVID-19-Pandemie und Störungen in der Lieferkette außergewöhnliche Leistungen gezeigt.
Die Auszeichnung erfolgt, während Biotricity eine kritische Lücke im Gesundheitswesen angeht, da über 100 Millionen Amerikaner Barrieren beim Zugang zu wichtigen Gesundheitsdiensten gegenüberstehen. Die proprietären Technologien zur Fernüberwachung des Unternehmens haben insbesondere bei hochriskanten Herzpatienten einen erheblichen Einfluss gehabt, wodurch medizinische Anbieter schnellere Interventionen sowohl in den USA als auch international durchführen können.
Der vollständige Bericht des Financial Times wird am 25. April 2025 veröffentlicht und ist für Abonnenten von US-Zeitungen sowie weltweit auf ft.com verfügbar.
- None.
- None.
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times’ list of The Americas’ Fastest-Growing Companies 2025. This recognition highlights Biotricity’s innovation in digital health and exceptional growth of
Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed revenue growth between 2020 and 2023. During this period, businesses faced significant economic obstacles, including the COVID-19 pandemic, supply chain disruptions, and rising interest rates.
In the face of these challenges, Biotricity has achieved standout growth, fueled by the rising demand for smart remote monitoring solutions. As of 2023, more than 100 million Americans face barriers to accessing essential healthcare services. This underscores the urgent need to increase accessibility to medical care by expanding remote monitoring services. Biotricity is leading this transformation with proprietary technologies that have redefined the standard of continuous remote monitoring for high-risk cardiac patients. Medical providers utilizing Biotricity’s solutions are enabled to deliver faster interventions, improving outcomes for thousands across the U.S. and internationally.
“Being recognized by the Financial Times as one of the fastest-growing companies in the Americas is a tremendous honor and a testament to the dedication of our team,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our mission to revolutionize chronic care management, particularly in the cardiac space, continues to gain momentum, and this milestone validates our approach to innovating in the healthcare landscape.”
The full list and special report will be published by the Financial Times on Tuesday, April 25, 2025, and will be distributed to its U.S. newspaper subscribers and globally on www.ft.com.
For more information about Biotricity and its remote patient monitoring solutions, visit www.biotricity.com or contact investors@biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
FAQ
What growth rate did Biotricity (BTCY) achieve to earn Financial Times recognition?
How many Americans does Biotricity (BTCY) aim to help with healthcare access?
What is Biotricity's (BTCY) main focus in healthcare technology?
When will the Financial Times publish the complete report featuring Biotricity (BTCY)?
What market challenges did Biotricity (BTCY) overcome during its growth period?
